Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Infiltration

PreclinicalSmall molecule

UUniversity of Seville

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Plantar FasciopathyNot yet recruiting

Plantar FasciopathyPreclinical

Not yet recruiting

Timeline

Expected Milestones

Q4 2026

N/ANot yet recruiting

Plantar Fasciopathy

NCT06671223

Clinical

Trials by Indication[1]

Plantar Fasciopathy1 trial

Effectiveness of Infiltrations in the Treatment of Plantar Fasciopathy

Not yet recruiting·UUniversity of Seville·N/A·NCT06671223·200 enrolled

Infiltration1 trial

Efficacy of Combining an Inferior Alveolar Nerve Block With a Buccal Infiltration

Completed·—·Phase 1/2·NCT06276842·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Infiltration. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Infiltration compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Infiltration. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Seville company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Seville

Related News